Back Palmitoiletanolamid BS Palmitoiletanolamida Spanish Palmitoyléthanolamide French Palmitoiletanolamide Italian パルミトイルエタノールアミド Japanese Palmitoylethanolamide Dutch Пальмитоилэтаноламид Russian Palmitoiltanolamid Serbo-Croatian Palmitoiltanolamid Serbian 十六酰胺乙醇 Chinese
 |
| |
| Names | |
|---|---|
| Preferred IUPAC name
N-(2-Hydroxyethyl)hexadecanamide[1] | |
Other names
| |
| Identifiers | |
3D model (JSmol)
|
|
| Abbreviations | PEA |
| ChEMBL | |
| ChemSpider | |
| ECHA InfoCard | 100.008.062 |
| EC Number |
|
| KEGG | |
| MeSH | palmidrol |
PubChem CID
|
|
| UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
| Properties | |
| C18H37NO2 | |
| Molar mass | 299.499 g·mol−1 |
| Appearance | White crystals |
| Density | 910 mg mL−1 |
| Melting point | 93 to 98 °C (199 to 208 °F; 366 to 371 K) |
| log P | 5.796 |
| Hazards | |
| Flash point | 323.9 °C (615.0 °F; 597.0 K) |
| Related compounds | |
Related compounds
|
|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
| |
Palmitoylethanolamide (PEA) is an endogenous fatty acid amide, and lipid modulator.[2]
A main target of PEA is proposed to be the peroxisome proliferator-activated receptor alpha (PPAR-α).[3][4] PEA also has affinity to cannabinoid-like G-coupled receptors GPR55 and GPR119.[5] PEA cannot strictly be considered a classic endocannabinoid because it lacks affinity for the cannabinoid receptors CB1 and CB2.[6]
- ^ NCBI-PubChem Staff (25 March 2005). "Compound Summary: Palmitoylethanolamide" (database entry). PubChem.NCBI.NLM.NIH.gov. Bethesda, MD: US NLM-National Center for Biotechnology Information (NCBI). Retrieved 26 February 2020.
- ^ Petrosino S, Di Marzo V (2017). "The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations". British Journal of Pharmacology. 174 (11): 1349–1365. doi:10.1111/bph.13580. PMC 5429331. PMID 27539936.
- ^ O'Sullivan SE (November 2007). "Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors". British Journal of Pharmacology. 152 (5): 576–82. doi:10.1038/sj.bjp.0707423. PMC 2190029. PMID 17704824.
- ^ Lo Verme J, Fu J, Astarita G, La Rana G, Russo R, Calignano A, Piomelli D (January 2005). "The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide". Molecular Pharmacology. 67 (1): 15–9. doi:10.1124/mol.104.006353. PMID 15465922. S2CID 12671741.
- ^ Godlewski G, Offertáler L, Wagner JA, Kunos G (September 2009). "Receptors for acylethanolamides-GPR55 and GPR119". Prostaglandins & Other Lipid Mediators. 89 (3–4): 105–11. doi:10.1016/j.prostaglandins.2009.07.001. PMC 2751869. PMID 19615459.
- ^ O'Sullivan SE, Kendall DA (August 2010). "Cannabinoid activation of peroxisome proliferator-activated receptors: potential for modulation of inflammatory disease". Immunobiology. 215 (8): 611–6. doi:10.1016/j.imbio.2009.09.007. PMID 19833407.